Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.

@article{Verhamme2010TolerabilityAP,
  title={Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.},
  author={Peter B. Verhamme and Steve Pakola and Thomas Jon Jensen and Kristina Berggren and Elisabeth Sonesson and Jean-Marie R. Saint-Remy and Torben Balchen and Ann Belmans and Geraldine Cahillane and Jason Stassen and Kathelijne Peerlinck and Steven Brian Glazer and Maxime Jacquemin},
  journal={Clinical therapeutics},
  year={2010},
  volume={32 6},
  pages={
          1205-20
        }
}
BACKGROUND TB-402, a human monoclonal antibody that partially inhibits Factor VIII activity (FVIII:C), is being developed as a long-acting antithrombotic agent. OBJECTIVES The primary goal of this study was to investigate the tolerability of TB-402 in healthy male volunteers. Secondary objectives were to determine the pharmacokinetics and pharmacodynamics of TB-402. METHODS In this ascending-dose study, healthy subjects aged 18 to 45 years were randomly assigned in a 2:1 ratio to receive TB… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Similar Papers

Loading similar papers…